

DAFTAR PUSTAKA

- Abancens, M., Bustos, V., Harvey, H., McBryan, J., & Harvey, B. J. (2020). Sexual Dimorphism in Colon Cancer. *Frontiers in Oncology*, 10(December), 1–27. <https://doi.org/10.3389/fonc.2020.607909>
- ACS. (2020a). Colorectal Cancer Causes, Risk Factors, and Prevention. *American Cancer Society*, 5.
- ACS. (2020b). Colorectal Cancer Facts and Figures 2020-2022. *American Cancer Society*, 66(11), 1–41. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf>
- Adamczyk-Gruszka O, Horecka-Lewitowicz A, Gruszka J, Wawszczak-Kasza M, Strzelecka A, Lewitowicz P. FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer. *J Clin Med*. 2022 Sep 15;11(18):5416. doi: 10.3390/jcm11185416. PMID: 36143062; PMCID: PMC9504491.
- Ahmed, M. (2020). Colon Cancer: A Clinician's Perspective in 2019. *Gastroenterology Research*, 13(1), 1–10. <https://doi.org/10.14740/gr1239>
- Aiman Mohtar, M., Syafruddin, S. E., Nasir, S. N., & Yew, L. T. (2020). Revisiting the roles of pro-metastatic epcam in cancer. *Biomolecules*, 10(2). <https://doi.org/10.3390/biom10020255>
- Alessandro Lugli, Richard Kirsch, et al, Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016, *Modern Pathology*, Volume 30, Issue 9, 2017
- Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study. *Int J Surg*. 2017 Jan;37:42-49. doi: 10.1016/j.ijsu.2016.08.528. Epub 2016 Sep 4. PMID: 27600906.
- American Cancer Society. (2020). About Colorectal Cancer What Is Colorectal Cancer? *American Cancer Society*, 1–15.
- Arnold, C. A., Lam-Himlin, D. M., & Montgomery, E. A. (2015). Colon. In *Atlas of Gastrointestinal Pathology*. Wolters Kluwer.
- Aphrothiti J. Hanrahan, Gopa Iyer, David B. Solit, 2 - Intracellular Signaling, Editor(s): John E. Niederhuber, James O. Armitage, James H. Doroshow, Michael B. Kastan, Joel E. Tepper, *Abeloff's Clinical Oncology* (Fifth Edition), Churchill Livingstone, 2014, Pages 22-39.e8, ISBN

9781455728657, <https://doi.org/10.1016/B978-1-4557-2865-7.00002-3>.
(<https://www.sciencedirect.com/science/article/pii/B9781455728657000023>)

- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y. (2018). Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. *Gastroenterology Research*, 11(4), 264–273. <https://doi.org/10.14740/gr1062w>
- Brown, T. C., Sankpal, N. V., & Gillanders, W. E. (2021). Functional implications of the dynamic regulation of EpCAM during epithelial-to-mesenchymal transition. *Biomolecules*, 11(7), 1–22. <https://doi.org/10.3390/biom11070956>
- Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villafior VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. *Oncotarget*. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. PMID: 28030802; PMCID: PMC5362545.
- Chai, X. B., Song, R. F., & Xu, F. (2015). Expression changes in epithelial cell adhesion molecule during colorectal cancer tumorigenesis. *Genetics and Molecular Research*, 14(3), 7624–7629. <https://doi.org/10.4238/2015.July.13.6>
- Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. *Cells*. 2019 Jun 18;8(6):614. doi: 10.3390/cells8060614. PMID: 31216761; PMCID: PMC6627960
- Damjanov, I., & Fan, F. (2013). Tumors of the Digestive System. In *Cancer Grading Manual* (Second). Springer.
- Dylla, S. J., Beviglia, L., Park, I. K., Chartier, C., Raval, J., Ngan, L., Pickell, K., Aguilar, J., Lazetic, S., Smith-Berdan, S., Clarke, M. F., Hoey, T., Lewicki, J., & Gurney, A. L. (2008). Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. *PLoS ONE*, 3(6). <https://doi.org/10.1371/journal.pone.0002428>
- Effendi-YS, R., & Rey, I. (2018). Cancer Stem Cells and Signaling Pathways in Colorectal Cancer. *The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy*, 19(1), 37. <https://doi.org/10.24871/191201837-41>
- Fuchs, Talia L. MD*,†,‡; Sioson, Loretta BSc*; Sheen, Amy BSc*; Jafari-Nejad, Kambin MD, FRCPA§; Renaud, Christopher J. MBBS*,†; Andrici, Juliana MBBS, PhD||; Ahadi, Mahsa MD, FRCPA*,†,‡; Chou, Angela PhD, FRCPA*,†,‡; Gill, Anthony J. MD, FRCPA*,†,‡. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. *The American Journal of Surgical Pathology* 44(4):p 536-544, April 2020. | DOI:

10.1097/PAS.0000000000001409

- Goldblum, J. R., Lamps, L. W., McKenney, J. K., & Myers, J. L. (2018). Large Bowel. In J. R. Goldblum (Ed.), *ROSAI AND ACKERMAN'S SURGICAL PATHOLOGY* (pp. 648–649). Elsevier.
- Gött H, Uhl E. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. *Int J Mol Sci*. 2022 Aug 4;23(15):8675. doi: 10.3390/ijms23158675. PMID: 35955806; PMCID: PMC9369421.
- Haggar, F. A., & Boushey, R. P. (2009). Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery*, 22(4), 191–197. <https://doi.org/10.1055/s-0029-1242458> Epithelial Neoplasms of the Colorectum. In *GASTROINTESTINAL AND LIVER PATHOLOGY* (Second). Elsevier Saunders.
- Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. *Clin Cancer Res*. 2016 Jan 1;22(1):259-67. doi: 10.1158/1078-0432.CCR-14-3212. Epub 2015 Sep 15. PMID: 26373574.
- Hu M, Zhang S. Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma. *Transl Cancer Res*. 2022 Sep;11(9):3222-3234. doi: 10.21037/tcr-22-1936. PMID: 36237262; PMCID: PMC9552259.
- J. Otte, *et al.* FGF signalling in the self-renewal of colon cancer organoids *Sci. Rep.*, 9 (1) (2019), p. 17365)
- Katoh, M., & Nakagama, H. (2013). *FGF Receptors: Cancer Biology and Therapeutics. Medicinal Research Reviews*, 34(2), 280–300. doi:10.1002/med.21288
- Knuchel S., Anderle P., Werfelli P., Diamantis E., Rüegg C. Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin $\alpha_v\beta_5$ -mediated adhesion. *Oncotarget*. 2015; 6: 14300-14317. Retrieved from <https://www.oncotarget.com/article/3883/text/>
- Kumar, Vinay., Abbas, Abul K., Aster, J. C. (2021). Neoplasia. In *Robbins & Cotran Pathologic Basis of Disease* (Tenth Edit, pp. 267–336).Elsevier. Kumar, V., Abbas, A. K., & Aster, J. C. (2018). Small and Large Intestines. In *ROBBINS BASIC PATHOLOGY* (Tenth). Elsevier. Lamps, L. W., Bellizzi, A. M., Frankel, W. L., Owens, S. R., & Yantiss, R. K. (2016). Neoplasm of The Colon. In *Neoplastic Gastrointestinal Pathology An Illustrated Guide*. demosMEDICAL.
- Li, L., Zheng, J., & Oltean, S. (2023). Regulation of Epithelial-Mesenchymal Transitions by Alternative Splicing: Potential New Area for Cancer

Therapeutics. *Genes*, 14(11), 2001. <https://doi.org/10.3390/genes14112001>

Li Y, Shi Y, Zhang X, Li P, Ma L, Hu P, Xu L, Dai Y, Xia S, Qiu H. FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer. *Biochim Biophys Acta Mol Basis Dis*. 2023 Apr;1869(4):166665. doi: 10.1016/j.bbadis.2023.166665. Epub 2023 Feb 11. PMID: 36781088.

Lotfollahzadeh S, Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2023 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470380/>

Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. *Nat Rev Clin Oncol*. 2021 Feb;18(2):101-115. doi: 10.1038/s41571-020-0422-y. Epub 2020 Sep 8. PMID: 32901132.

Majek, O., Gondos, A., Jansen, L., Emrich, K., Holleczech, B., Katalinic, A., Nennecke, A., Eberle, A., & Brenner, H. (2013). Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany. *PLoS ONE*, 8(7), 1–7. <https://doi.org/10.1371/journal.pone.0068077>

Mangone, L., Pinto, C., Mancuso, P., Ottone, M., Bisceglia, I., Chiaranda, G., Michiara, M., Vicentini, M., Carrozzi, G., Ferretti, S., Falcini, F., Hassan, C., & Rossi, P. G. (2021). Colon cancer survival differs from right side to left side and lymph node harvest number matter. *BMC Public Health*, 21(1), 1–10. <https://doi.org/10.1186/s12889-021-10746-4>

Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodríguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. *Int J Mol Sci*. 2017 Jan 19;18(1):197. doi: 10.3390/ijms18010197. PMID: 28106826; PMCID: PMC5297828

Martin, T. A., Mason, M. D., & Jiang, W. G. (2011). Tight junctions in cancer Metastasis. *Frontiers in Bioscience*, 16, 898–936. MENKES. (2018). PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA KANKER KOLOREKTAL. *KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA*.

Matsuda Yoko, Tse Gary, Ueda Junji. Ishiwata, Toshiyuki Fibroblast Growth Factor Receptor 2: Expression, Roles, and Potential As a Novel Molecular Target for Colorectal Cancer. 2012 <https://doi.org/10.1155/2012/574768>. Pathology Research International. Hindawi Publishing Corporatio

Matsuda, Y.; Ishiwata, T.; Yamahatsu, K.; Kawahara, K.; Hagio, M.; Peng, W.X.; Yamamoto, T.; Nakazawa, N.; Seya, T.; Ohaki, Y.; et al. Overexpressed fibroblast

growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer. *Cancer Lett.* 2011, 309, 209–219. [CrossRef])

M. A. Yastrebova^{1*}, A. I. Khamidullina¹, V. V. Tatarskiy^{1,2}, A. M. Scherbakov²
¹ Institute of Gene Biology, Russian Academy of Sciences, Moscow, 119334 Russia
² Blokhin National Medical Research Center of Oncology, Moscow, 115478 Russia
* E-mail: ritayastrebova2009@gmail.com Received June 29, 2020; in final form, September 04, 2020 DOI: 10.32607/actanaturae.11062

Mescher, A. L. (2016). Digestive Tract. In *Junqueira's Basic Histology Text and Atlas* (Fourteenth). Lange.

Molavi, D. W. (2018). Colon and Appendix. In *The Practice of Surgical Pathology A Beginner's Guide to the Diagnostic Process* (Second). Springer. 2017-204739

Monica Kong-Beltran, Daniel J. Donoghue, CHAPTER 264 - Signaling from FGF Receptors in Development and Disease, Editor(s): Ralph A. Bradshaw, Edward A. Dennis, Handbook of Cell Signaling, Academic Press, 2003, Pages 861-865, ISBN 9780121245467, <https://doi.org/10.1016/B978-012124546-7/50625-2>.
<https://www.sciencedirect.com/science/article/pii/B9780121245467506252>)

Nagtegaal, I., Arends, MJ; Odze, R., & Lam, A. (2019). Tumours of the colon and rectum. In *WHO Classification of Tumours Digestive System Tumours* (5th ed.). World Health Organization. Nieto, M. A., Huang, R. Y. Y. J., Jackson, R. A. A., & Thiery, J. P. P. (2016). Emt: 2016. *Cell*, 166(1), 21–45.
<https://doi.org/10.1016/j.cell.2016.06.028>

Noffsinger, A. E. (2017). Epithelial Neoplasms of the Colon. In *Fenoglio-Preiser's Gastrointestinal Pathology* (Fourth). Wolters Kluwer.

Odze, R. D., & Goldblum, J. R. (2015). Epithelial Neoplasms of the Large Intestine. In *Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas* (Third). Elsevier Saunders.

Pacini, L.; Jenks, A.D.; Lima, N.C.; Huang, P.H. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. *Cells* **2021**, 10, 1154.
<https://doi.org/10.3390/cells10051154>

Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, Fourie Zirkelbach J, Charlab R, Liu J, Yang Y, Lemery SJ, Pazdur R, Theoret MR, Fashoyin-Aje LA. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. *Clin Cancer*

Res. 2023 Mar 1;29(5):838-842. doi: 10.1158/1078-0432.CCR-22-2036. PMID: 36206041; PMCID: PMC9991984.

- Piao Li, Tingting Huang, Qi Zou, Dian Liu, Yihua Wang, Ximin Tan, Yao Wei, Hong Qiu; FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. *J Immunol* 15 May 2019; 202 (10): 3065–3075. <https://doi.org/10.4049/jimmunol.1801199>
- Porta, R.; Borea, R.; Coelho, A.; Khan, S.; Araújo, A.; Reclusa, P.; Franchina, T.; Van Der Steen, N.; Van Dam, P.; Ferri, J.; et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. *Crit. Rev. Oncol. Hematol.* 2017, 113, 256–267. [CrossRef])
- Ratti, M.; Orlandi, E.; Hahne, J.C.; Vecchia, S.; Citterio, C.; Anselmi, E.; Toscani, I.; Ghidini, M. Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment. *Biomedicines* **2023**, *11*, 2650. <https://doi.org/10.3390/biomedicines11102650>
- Rawla, P., Sunkara, T., & Barsouk, A. (2019). Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Przegląd Gastroenterologiczny*, 14(2),89–103.<https://doi.org/10.5114/pg.2018.81072>
- Reicher, A.; Harris, A.L.; Prinz, F.; Kiesslich, T.; Wei, M.; Öllinger, R.; Rad, R.; Pichler, M.; Kwong, L.N. Generation of An Endogenous FGFR2–BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. *Int. J. Mol. Sci.* **2020**, *21*, 2460. <https://doi.org/10.3390/ijms21072460>
- Ruan, R., Li, L., Li, X. *et al.* Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. *Mol Cancer* **22**, 60 (2023). <https://doi.org/10.1186/s12943-023-01761-7>
- Sacchetti, A., Teeuwssen, M., Verhagen, M., Joosten, R., Xu, T., Stabile, R., van der Steen, B., Watson, M. M., Gusinac, A., Kim, W. K., Ubink, I., Van de Werken, H. J. G., Fumagalli, A., Paauwe, M., Van Rheenen, J., Sansom, O. J., Kranenburg, O., & Fodde, R. (2021). Phenotypic plasticity underlies local invasion and distant metastasis incolon cancer. *ELife*, 10, 1–28. <https://doi.org/10.7554/eLife.61461>
- Sarrand J, Soyfoo MS. Involvement of Epithelial-Mesenchymal Transition (EMT) in Autoimmune Diseases. *International Journal of Molecular Sciences*. 2023; 24(19):14481. <https://doi.org/10.3390/ijms241914481>
- Shoji H, Yamada Y, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance. *Anticancer Res.* 2015 Sep;35(9):5055-61. PMID: 26254407.

- Siegel, R. L., Jakubowski, C. D., Fedewa, S. A., & Davis, A. (2022). *Colorectal Cancer in the Young : Epidemiology , Prevention , Management*. 75–88
- Sisir Nandi¹, and Manish C. Bagchi^{2,*} ¹ Division of Pharmaceutical Chemistry, Global Institute of Pharmaceutical Education and Research, Affiliated to Uttarakhand Technical University, Kashipur-244713, India ² Formerly of School of Bio-Science and Engineering, Jadavpur University, Raja S.C. Mullick Road, Kolkata 700032, India
- Teeuwssen, M., & Fodde, R. (2019). Cell heterogeneity and phenotypic plasticity in metastasis formation: The case of colon cancer. *Cancers*, 11(9). <https://doi.org/10.3390/cancers11091368>
- Tiong, Kai Hung, Mah, Li Yen, Leong, Chee-Onn. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. 2013. Doi: 10.1007/s10495-013-0886-7
- Turner, N., & Grose, R. (2010). *Fibroblast growth factor signalling: from development to cancer*. *Nature Reviews Cancer*, 10(2), 116–129. doi:10.1038/nrc2780
- Valtorta, E., Martino, C., Sartore-Bianchi, A., Penault-Llorca, F., Viale, G., Risio, M., ... Gambacorta, M. (2015). *Assessment of a HER2 scoring system for colorectal cancer: results from a validation study*. *Modern Pathology*, 28(11), 1481–1491. doi:10.1038/modpathol.2015.98
10.1038/modpathol.2015.98
- Vuik, F. E. R., Nieuwenburg, S. A. V., Bardou, M., Lansdorp-Vogelaar, I., Dinis-Ribeiro, M., Bento, M. J., Zadnik, V., Pellisé, M., Esteban, L., Kaminski, M. F., Suchanek, S., Ngo, O., Májek, O., Leja, M., Kuipers, E. J., & Spaander, M. C. W. (2019). Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. *Gut*, 1820– 1826. <https://doi.org/10.1136/gutjnl-2018-317592>
- Wang, X., Cao, Y., Ding, M., Liu, J., Zuo, X., Li, H., Fan, R. (2021). Oncological and prognostic impact of lymphovascular invasion in Colorectal Cancer patients. *International Journal of Medical Sciences*, 18(7), 1721-1729. <https://doi.org/10.7150/ijms.53555>.
- Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, Ni Z, Zhang B, Zhang D, Luo F, Chen H, Sun X, Feng JQ, Qi H, Chen L. FGF/FGFR signaling in health and disease. *Signal Transduct Target Ther*. 2020 Sep 2;5(1):181. doi: 10.1038/s41392-020-00222-7. PMID: 32879300; PMCID: PMC7468161.
- Yang, J., Antin, P., Berx, G., Blanpain, et al, EMT International Association (TEMTIA) (2020). Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature reviews. Molecular cell biology*, 21(6), 341–352.

<https://doi.org/10.1038/s41580-020-0237-9>

- Yasui, Hisateru, et al. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study JO - International Journal of Colorectal Disease, 2022, <https://doi.org/10.1007/s00384-022-04162-2>
- Y. Sun, *et al.* A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients *Ann. Transl. Med.*, 8 (20) (2020), p. 1290)
- Zhang, N., Ng, A. S., Cai, S., Li, Q., Yang, L., & Kerr, D. (2021). *Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer. The Lancet Oncology*, 22(8), e358–e368. doi:10.1016/s1470-2045(21)00343-0
- Zhou WY, Zheng H, Du XL, Yang JL. Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. *Cancer Biol Med.* 2016 Jun;13(2):260-8. doi: 10.20892/j.issn.2095-3941.2015.0102. PMID: 27458533; PMCID: PMC4944539

LAMPIRAN



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Aguswalm Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 607/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 8 Agustus 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24060469	No Sponsor	
Peneliti Utama	dr. Andi Marcha Rianti	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI FIBROBLAST GROWTH FACTOR RECEPTORS 1 (FGFR 1), FIBROBLAST GROWTH FACTOR RECEPTORS 2 (FGFR2), DAN ZINC FINGER E-BOX BINDING HOMEBOX 1 (ZEB 1), DENGAN GRADING HISTOPATOLOGI, INVASI LIMFOVASKULAR, DAN METASTASIS KE KELENJAR GETAH BENING PA		
No Versi Protokol	1	Tanggal Versi	26 Juni 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Laboratorium PA Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 8 Agustus 2024 sampai 8 Agustus 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

